Antiphospholipid antibodies in patients with calcific aortic valve stenosis

Abstract Objectives The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calci...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 62; no. 3; pp. 1187 - 1196
Main Authors Plunde, Oscar, Svenungsson, Elisabet, Ferrannini, Giulia, Franco-Cereceda, Anders, Bäck, Magnus
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.03.2023
Subjects
Online AccessGet full text
ISSN1462-0324
1462-0332
1462-0332
DOI10.1093/rheumatology/keac466

Cover

Abstract Abstract Objectives The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined. Methods A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays. Results The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% – 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms. Conclusions aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets.
AbstractList The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined. A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays. The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% - 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms. aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets.
Abstract Objectives The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined. Methods A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays. Results The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% – 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms. Conclusions aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets.
The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined.OBJECTIVESThe antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined.A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays.METHODSA total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays.The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% - 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms.RESULTSThe prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% - 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms.aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets.CONCLUSIONSaPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets.
Author Plunde, Oscar
Franco-Cereceda, Anders
Svenungsson, Elisabet
Bäck, Magnus
Ferrannini, Giulia
Author_xml – sequence: 1
  givenname: Oscar
  orcidid: 0000-0003-1343-2198
  surname: Plunde
  fullname: Plunde, Oscar
  email: oscar.persson@ki.se
– sequence: 2
  givenname: Elisabet
  orcidid: 0000-0003-3396-3244
  surname: Svenungsson
  fullname: Svenungsson, Elisabet
– sequence: 3
  givenname: Giulia
  surname: Ferrannini
  fullname: Ferrannini, Giulia
– sequence: 4
  givenname: Anders
  surname: Franco-Cereceda
  fullname: Franco-Cereceda, Anders
– sequence: 5
  givenname: Magnus
  surname: Bäck
  fullname: Bäck, Magnus
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35961031$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:150551168$$DView record from Swedish Publication Index
BookMark eNqNUctu2zAQJIoUzaP9g6LQsRfVfEik1EOBIOgLCdBLeiZW9CpmQ5OqSNnw35eGHCPpJTkQu9idmeXOnpMTHzwS8p7RT4y2YjGucFpDCi7c7Rb3CKaS8hU5Y5XkJRWCnxxzXp2S8xj_UEprJpo35FTUrWRUsDNyfemTHVYh5ufsYJcF5EIXlhZjYX0xQLLoUyy2Nq0KA87Y3poCwphy2IDbYBET-hBtfEte9-AivjvEC_L729fbqx_lza_vP68ub0pTNTKViAqUWLaSt32HrKeM910PjZB1q1re1lxR4Fx2UnaqVg1jjQIQKCgKyXshLkg9605-gN0WnNPDaNcw7jSjem-OfmyOPpiTeeXMi1scpu5ICmD1oXSfM9RVzeqqzvgvMz531rg02YcR3BPa0463K30XNrptlWJMZYGPB4Ex_J0wJr220aBz4DFMUedFOWsqzvfQD49nHYc8XCoDqhlgxhDjiP1Ld_78H83YlG8a9j-27jnyYiaHaXjZuH9aE9bS
CitedBy_id crossref_primary_10_1038_s41584_024_01110_y
crossref_primary_10_1016_j_clim_2024_109906
crossref_primary_10_1016_j_clim_2023_109790
crossref_primary_10_1093_ehjopen_oeac084
Cites_doi 10.1016/j.jacc.2017.02.058
10.1161/CIRCRESAHA.108.192765
10.1016/j.jacc.2019.01.070
10.1161/01.CIR.90.2.844
10.1136/heartjnl-2020-318733
10.1038/nrdp.2017.103
10.1093/eurheartj/ehy696
10.1111/j.1538-7836.2006.01753.x
10.1172/JCI39828
10.1016/S0735-1097(96)00563-3
10.1161/CIRCULATIONAHA.111.028522
10.1016/j.atherosclerosis.2007.05.030
10.1055/s-0039-1685453
10.1038/nrdp.2016.6
10.1016/j.jacbts.2021.02.005
10.1111/jth.13379
10.1016/j.jacbts.2021.07.008
10.1016/j.ijcard.2019.10.042
10.1056/NEJMoa1109034
10.1161/CIRCGEN.119.002710
10.1111/joim.13409
10.1056/NEJMra1313875
10.1136/ard.2009.115535
10.1007/s00125-019-05019-0
10.1124/jpet.110.177915
10.7326/M18-2130
10.1111/jth.15585
10.1515/cclm-2013-0741
10.3389/fimmu.2019.00487
10.1161/CIRCULATIONAHA.121.054182
10.1186/s13075-019-1878-y
10.1371/journal.pone.0156407
10.1161/CIRCRESAHA.110.234146
10.1101/gr.1239303
10.1016/j.celrep.2018.09.002
10.1046/j.1365-2249.1997.d01-948.x
10.1016/j.jacc.2015.07.020
10.1016/S0092-8674(01)00628-6
10.1161/CIRCGENETICS.110.948935
10.3389/fcvm.2019.00018
10.1161/ATVBAHA.118.311504
10.1056/NEJMoa073003
ContentType Journal Article
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2022
The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2022
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
DBID TOX
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D8T
ZZAVC
ADTOC
UNPAY
DOI 10.1093/rheumatology/keac466
DatabaseName Oxford Journals Open Access Collection
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Freely available online
SwePub Articles full text
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 1196
ExternalDocumentID 10.1093/rheumatology/keac466
oai_swepub_ki_se_451545
PMC9977117
35961031
10_1093_rheumatology_keac466
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: 2019–01486; 2018–02535
– fundername: ;
– fundername: ;
  grantid: 20170365; 20170038
– fundername: ;
  grantid: 20180571; 20170257
– fundername: ;
  grantid: SLS-713911
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABQTQ
ABVGC
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TOX
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
AAYXX
AHGBF
AJBYB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AGQPQ
AOWAS
D8T
ZZAVC
ADTOC
UNPAY
ID FETCH-LOGICAL-c486t-ee7a73d9629fbe1f012fbfa8365979295270a226b66b75781187aa3e30e362f33
IEDL.DBID UNPAY
ISSN 1462-0324
1462-0332
IngestDate Sun Oct 26 04:08:08 EDT 2025
Mon Oct 20 03:22:57 EDT 2025
Tue Sep 30 17:16:45 EDT 2025
Thu Oct 02 10:07:51 EDT 2025
Thu Apr 03 06:57:20 EDT 2025
Wed Oct 01 04:43:26 EDT 2025
Thu Apr 24 23:06:04 EDT 2025
Wed Apr 02 07:05:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords antiphospholipid syndrome
transcriptomics
aPL
calcific aortic valve stenosis
SLE
heart valve disease
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
https://creativecommons.org/licenses/by-nc/4.0
The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c486t-ee7a73d9629fbe1f012fbfa8365979295270a226b66b75781187aa3e30e362f33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Anders Franco-Cereceda and Magnus Bäck contributed equally to this study.
ORCID 0000-0003-3396-3244
0000-0003-1343-2198
OpenAccessLink https://proxy.k.utb.cz/login?url=https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keac466/45600133/keac466.pdf
PMID 35961031
PQID 2702184227
PQPubID 23479
PageCount 10
ParticipantIDs unpaywall_primary_10_1093_rheumatology_keac466
swepub_primary_oai_swepub_ki_se_451545
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9977117
proquest_miscellaneous_2702184227
pubmed_primary_35961031
crossref_primary_10_1093_rheumatology_keac466
crossref_citationtrail_10_1093_rheumatology_keac466
oup_primary_10_1093_rheumatology_keac466
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-03-01
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Pericleous (2023030119163482700_) 2016; 11
Palli (2023030119163482700_) 2019; 10
John (2023030119163482700_) 2018; 25
Svenungsson (2023030119163482700_) 2010; 69
Sáinz-Jaspeado (2023030119163482700_) 2021; 144
Oke (2023030119163482700_) 2019; 21
Parra-Izquierdo (2023030119163482700_) 2018; 38
Stewart (2023030119163482700_) 1997; 29
Selmi (2023030119163482700_) 2020; 300
Sarajlic (2023030119163482700_) 2021; 6
Thanassoulis (2023030119163482700_) 2013; 368
Kelchtermans (2023030119163482700_) 2016; 14
Svenungsson (2023030119163482700_) 2022; 291
Yu (2023030119163482700_) 2011; 337
Zuily (2023030119163482700_) 2011; 124
Plunde (2023030119163482700_) 2020; 13
Hasunuma (2023030119163482700_) 1997; 107
Corban (2023030119163482700_) 2017; 69
New (2023030119163482700_) 2011; 108
Vandevelde (2023030119163482700_) 2022; 20
Bäck (2023030119163482700_) 2021
Glaser (2023030119163482700_) 2021; 107
Bouchareb (2023030119163482700_) 2019; 40
Lindman (2023030119163482700_) 2016; 2
Yuan (2023030119163482700_) 2020; 63
Salina (2023030119163482700_) 2002; 108
Sellers (2023030119163482700_) 2021; 6
Ramesh (2023030119163482700_) 2011; 121
Remmers (2023030119163482700_) 2007; 357
Zheng (2023030119163482700_) 2019; 73
Otto (2023030119163482700_) 1994; 90
Shannon (2023030119163482700_) 2003; 13
Hollerbach (2023030119163482700_) 2019; 119
Otto (2023030119163482700_) 2014; 371
Capoulade (2023030119163482700_) 2015; 66
Folkersen (2023030119163482700_) 2010; 3
Grosso (2023030119163482700_) 2019; 170
Van der Heiden (2023030119163482700_) 2008; 196
Miyakis (2023030119163482700_) 2006; 4
Nyman (2023030119163482700_) 2014; 52
AbouAlaiwi (2023030119163482700_) 2009; 104
Mathieu (2023030119163482700_) 2019; 6
Schreiber (2023030119163482700_) 2018; 4
References_xml – volume: 69
  start-page: 2317
  year: 2017
  ident: 2023030119163482700_
  article-title: Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2017.02.058
– volume: 104
  start-page: 860
  year: 2009
  ident: 2023030119163482700_
  article-title: Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.108.192765
– volume: 73
  start-page: 2150
  year: 2019
  ident: 2023030119163482700_
  article-title: Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2019.01.070
– volume: 90
  start-page: 844
  year: 1994
  ident: 2023030119163482700_
  article-title: Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies
  publication-title: Circulation
  doi: 10.1161/01.CIR.90.2.844
– volume: 107
  start-page: 1167
  year: 2021
  ident: 2023030119163482700_
  article-title: Relative survival after aortic valve surgery in patients with bicuspid aortic valves
  publication-title: Heart
  doi: 10.1136/heartjnl-2020-318733
– volume: 4
  start-page: 17103
  year: 2018
  ident: 2023030119163482700_
  article-title: Antiphospholipid syndrome
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2017.103
– volume: 40
  start-page: 1362
  year: 2019
  ident: 2023030119163482700_
  article-title: Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehy696
– volume: 4
  start-page: 295
  year: 2006
  ident: 2023030119163482700_
  article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2006.01753.x
– volume: 121
  start-page: 120
  year: 2011
  ident: 2023030119163482700_
  article-title: Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2
  publication-title: J Clin Invest
  doi: 10.1172/JCI39828
– volume: 29
  start-page: 630
  year: 1997
  ident: 2023030119163482700_
  article-title: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study
  publication-title: J Am Coll Cardiol
  doi: 10.1016/S0735-1097(96)00563-3
– volume: 124
  start-page: 215
  year: 2011
  ident: 2023030119163482700_
  article-title: Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.111.028522
– volume: 196
  start-page: 542
  year: 2008
  ident: 2023030119163482700_
  article-title: Endothelial primary cilia in areas of disturbed flow are at the base of atherosclerosis
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2007.05.030
– volume: 119
  start-page: 1147
  year: 2019
  ident: 2023030119163482700_
  article-title: Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors
  publication-title: Thromb Haemost
  doi: 10.1055/s-0039-1685453
– volume: 2
  start-page: 16006
  year: 2016
  ident: 2023030119163482700_
  article-title: Calcific aortic stenosis
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2016.6
– volume: 6
  start-page: 403
  year: 2021
  ident: 2023030119163482700_
  article-title: Artificial intelligence models reveal sex-specific gene expression in aortic valve calcification
  publication-title: JACC Basic Transl Sci
  doi: 10.1016/j.jacbts.2021.02.005
– volume: 14
  start-page: 1530
  year: 2016
  ident: 2023030119163482700_
  article-title: IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.13379
– volume: 6
  start-page: 1007
  year: 2021
  ident: 2023030119163482700_
  article-title: Platelets: implications in aortic valve stenosis and bioprosthetic valve dysfunction from pathophysiology to clinical care
  publication-title: . JACC Basic Transl Sci
  doi: 10.1016/j.jacbts.2021.07.008
– volume: 300
  start-page: 209
  year: 2020
  ident: 2023030119163482700_
  article-title: Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2019.10.042
– volume: 368
  start-page: 503
  year: 2013
  ident: 2023030119163482700_
  article-title: Genetic associations with valvular calcification and aortic stenosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1109034
– volume: 13
  start-page: e002710
  year: 2020
  ident: 2023030119163482700_
  article-title: FADS1 (Fatty Acid Desaturase 1) genotype associates with aortic valve FADS mRNA expression, fatty acid content and calcification
  publication-title: Circ Genom Precis Med
  doi: 10.1161/CIRCGEN.119.002710
– volume: 291
  start-page: 327
  year: 2022
  ident: 2023030119163482700_
  article-title: Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries
  publication-title: J Intern Med
  doi: 10.1111/joim.13409
– volume: 371
  start-page: 744
  year: 2014
  ident: 2023030119163482700_
  article-title: Aortic-valve stenosis–from patients at risk to severe valve obstruction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1313875
– volume: 69
  start-page: 834
  year: 2010
  ident: 2023030119163482700_
  article-title: A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2009.115535
– volume: 63
  start-page: 116
  year: 2020
  ident: 2023030119163482700_
  article-title: Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study
  publication-title: Diabetologia
  doi: 10.1007/s00125-019-05019-0
– volume: 337
  start-page: 16
  year: 2011
  ident: 2023030119163482700_
  article-title: Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.177915
– volume: 170
  start-page: 277
  year: 2019
  ident: 2023030119163482700_
  article-title: Antiphospholipid antibodies in patients with myocardial infarction
  publication-title: Ann Intern Med
  doi: 10.7326/M18-2130
– volume: 20
  start-page: 508
  year: 2022
  ident: 2023030119163482700_
  article-title: Semiquantitative interpretation of anticardiolipin and anti-β2-glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.15585
– volume: 52
  start-page: 815
  year: 2014
  ident: 2023030119163482700_
  article-title: The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2013-0741
– volume: 10
  start-page: 487
  year: 2019
  ident: 2023030119163482700_
  article-title: Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00487
– volume: 144
  start-page: 1629
  year: 2021
  ident: 2023030119163482700_
  article-title: Palmdelphin regulates nuclear resilience to mechanical stress in the endothelium
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.121.054182
– volume: 21
  start-page: 107
  year: 2019
  ident: 2023030119163482700_
  article-title: High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
  publication-title: Arthritis Res Ther
  doi: 10.1186/s13075-019-1878-y
– start-page: 2016
  volume-title: Cardiovasc Res
  year: 2021
  ident: 2023030119163482700_
– volume: 11
  start-page: e0156407
  year: 2016
  ident: 2023030119163482700_
  article-title: Measuring IgA Anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome
  publication-title: PLoS one
  doi: 10.1371/journal.pone.0156407
– volume: 108
  start-page: 1381
  year: 2011
  ident: 2023030119163482700_
  article-title: Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.110.234146
– volume: 13
  start-page: 2498
  year: 2003
  ident: 2023030119163482700_
  article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks
  publication-title: Genome Res
  doi: 10.1101/gr.1239303
– volume: 25
  start-page: 95
  year: 2018
  ident: 2023030119163482700_
  article-title: IFIT1 exerts opposing regulatory effects on the inflammatory and interferon gene programs in LPS-activated human macrophages
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.09.002
– volume: 107
  start-page: 569
  year: 1997
  ident: 2023030119163482700_
  article-title: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages
  publication-title: Clin Exp Immunol
  doi: 10.1046/j.1365-2249.1997.d01-948.x
– volume: 66
  start-page: 1236
  year: 2015
  ident: 2023030119163482700_
  article-title: Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2015.07.020
– volume: 108
  start-page: 97
  year: 2002
  ident: 2023030119163482700_
  article-title: Cytoplasmic dynein as a facilitator of nuclear envelope breakdown
  publication-title: Cell
  doi: 10.1016/S0092-8674(01)00628-6
– volume: 3
  start-page: 365
  year: 2010
  ident: 2023030119163482700_
  article-title: Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease
  publication-title: Circ Cardiovasc Genet
  doi: 10.1161/CIRCGENETICS.110.948935
– volume: 6
  start-page: 18
  year: 2019
  ident: 2023030119163482700_
  article-title: Autotaxin and lipoprotein metabolism in calcific aortic valve disease
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2019.00018
– volume: 38
  start-page: 2148
  year: 2018
  ident: 2023030119163482700_
  article-title: Calcification induced by type I interferon in human aortic valve interstitial cells is larger in males and blunted by a janus kinase inhibitor
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.118.311504
– volume: 357
  start-page: 977
  year: 2007
  ident: 2023030119163482700_
  article-title: STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa073003
SSID ssj0005138
Score 2.4370852
Snippet Abstract Objectives The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or...
The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric...
SourceID unpaywall
swepub
pubmedcentral
proquest
pubmed
crossref
oup
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1187
SubjectTerms Aged
Antibodies, Antiphospholipid
Antiphospholipid Syndrome - complications
Aortic Valve
Aortic Valve Stenosis - etiology
Clinical Science
Female
Humans
Immunoglobulin G
Lupus Erythematosus, Systemic - complications
Male
Pregnancy
Title Antiphospholipid antibodies in patients with calcific aortic valve stenosis
URI https://www.ncbi.nlm.nih.gov/pubmed/35961031
https://www.proquest.com/docview/2702184227
https://pubmed.ncbi.nlm.nih.gov/PMC9977117
http://kipublications.ki.se/Default.aspx?queryparsed=id:150551168
https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keac466/45600133/keac466.pdf
UnpaywallVersion publishedVersion
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1462-0332
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005138
  issn: 1462-0324
  databaseCode: KQ8
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1462-0332
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0005138
  issn: 1462-0324
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1462-0332
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005138
  issn: 1462-0324
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1Lj9MwEB7tdiUeB54LhMfKSAhxSbaxUyc5VohlBdqFw1Yqp8hObDVqlUSbBgS_gp_MuHZKA0IsFw6totQzSu0vmZl45huAFzTVMRoy7nOutR8lUe4nTFN_TEXIOc15IUy989k5P51F7-aT-R7UfS2McFnhQV_ScLlQHfpum3fMx25fvE8a85tC_6QgSNlw8BKfKRHnx9HGqDPWnwhQah8O-ASd9xEczM4_Tj_ZGiS8RGbb4NpjRvtiuz_oHhizQYHcjp_6e7qlIyW9Cde7qhFfv4jVaseondyG7_102FyWZdCtZZB_-4Up8j_O1x245RxkMrW67sKequ7BtTOXAnAf3k-rddks6hY_q7IpC4LYKGVtsiFJWRFHFNsS84aZIAI3SYdE1EYhwfvqsyKI7Kpuy_YQZidvLl6f-q4jhJ9HCV_7SsUiZkXKEWJShRqtq5ZaJAwXM0ZHb0LjsUCHUnIuDVG_6aUuBFNsrNBQa8YewKiqK_UISFLIIkfRVKYYEYcao2kuGRdRJDDgoNQD1i9tlju6dNO1Y5XZbXuW7U5e5ubKA38r1Vi6kL-Mf4ULd8Whz3toZfgIMPs6olJ112ampBADdUpjDx5aqG01MkS56eThQTwA4XaAoRcf_lKViw3NeIqhQRiizpcWrgMRd2qJRyqLJsYR9yDYwvlK_-jxvwo8gRsUfUybAvgURuvLTj1Dn3Atj2D_7TzE74sP8yN3T_8A6nBtjA
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3di9QwEB_OPdDzwW_P-kUEEV_a2ybdtH1cDo9DucMHF86nkrQJW3Zpy7VV9K_wT3aySfe2ini--FAobWbYTX7tzDQzvwF4TVMdoyHjPuda-1ES5X7CNPWnVISc05wXwtQ7n53z00X0_mJ2sQf1UAsjXFZ4MJQ0XC5Vj77b5hvzkdsXH5LG_KbQVxQEKRsPXuE7JeL8KNoYdcaGCwFK3YB9PkPnfQL7i_OP88-2Bgl_IrNtcO05o0Ox3R90j4zZqEBux0_9Pd3SkZLehlt91YhvX8V6vWPUTu7Cj2E6bC7LKug7GeTff2GK_I_zdQ_uOAeZzK2u-7Cnqgdw88ylADyED_OqK5tl3eKxLpuyIIiNUtYmG5KUFXFEsS0xX5gJInCTdEhEbRQSfK6-KILIruq2bB_B4uTdp-NT33WE8PMo4Z2vVCxiVqQcISZVqNG6aqlFwnAxY3T0ZjSeCnQoJefSEPWbXupCMMWmCg21ZuwxTKq6Uk-AJIUschRNZYoRcagxmuaScRFFAgMOSj1gw9JmuaNLN1071pndtmfZ7uRlbq488LdSjaUL-cv4t7hw1xz6aoBWhq8As68jKlX3bWZKCjFQpzT24NBCbauRIcpNJw8P4hEItwMMvfj4TlUuNzTjKYYGYYg631i4jkTcpRWeqSyaGUfcg2AL52v9o6f_KvAMDij6mDYF8DlMustevUCfsJMv3XP8E9k7a38
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiphospholipid+antibodies+in+patients+with+calcific+aortic+valve+stenosis&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Plunde%2C+Oscar&rft.au=Svenungsson%2C+Elisabet&rft.au=Ferrannini%2C+Giulia&rft.au=Franco-Cereceda%2C+Anders&rft.date=2023-03-01&rft.pub=Oxford+University+Press&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=62&rft.issue=3&rft.spage=1187&rft.epage=1196&rft_id=info:doi/10.1093%2Frheumatology%2Fkeac466&rft_id=info%3Apmid%2F35961031&rft.externalDocID=PMC9977117
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon